As of 2025-07-11, the Relative Valuation of Madrigal Pharmaceuticals Inc (MDGL) is (440.54) USD. This relative valuation is based on P/E multiples. With the latest stock price at 314.64 USD, the upside of Madrigal Pharmaceuticals Inc based on Relative Valuation is -240.0%.
The range of the Relative Valuation is (439.21) - (479.78) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 24.9x - 27.2x | 26.0x |
| Forward P/E multiples | 19.1x - 28.7x | 23.9x |
| Fair Price | (439.21) - (479.78) | (440.54) |
| Upside | -239.6% - -252.5% | -240.0% |
| Date | P/E |
| 2025-07-09 | -17.49 |
| 2025-07-08 | -16.30 |
| 2025-07-07 | -16.39 |
| 2025-07-03 | -16.94 |
| 2025-07-02 | -17.02 |
| 2025-07-01 | -17.02 |
| 2025-06-30 | -17.16 |
| 2025-06-27 | -17.05 |
| 2025-06-26 | -16.98 |
| 2025-06-25 | -15.74 |
| 2025-06-24 | -16.16 |
| 2025-06-23 | -16.04 |
| 2025-06-20 | -16.20 |
| 2025-06-18 | -16.03 |
| 2025-06-17 | -15.85 |
| 2025-06-16 | -16.16 |
| 2025-06-13 | -16.76 |
| 2025-06-12 | -16.85 |
| 2025-06-11 | -16.69 |
| 2025-06-10 | -16.01 |
| 2025-06-09 | -15.89 |
| 2025-06-06 | -15.77 |
| 2025-06-05 | -15.54 |
| 2025-06-04 | -15.84 |
| 2025-06-03 | -16.12 |
| 2025-06-02 | -15.46 |
| 2025-05-30 | -15.61 |
| 2025-05-29 | -15.30 |
| 2025-05-28 | -15.36 |
| 2025-05-27 | -15.40 |
| 2025-05-23 | -15.17 |
| 2025-05-22 | -15.50 |
| 2025-05-21 | -15.72 |
| 2025-05-20 | -16.60 |
| 2025-05-19 | -16.48 |
| 2025-05-16 | -16.50 |
| 2025-05-15 | -16.54 |
| 2025-05-14 | -16.04 |
| 2025-05-13 | -16.74 |
| 2025-05-12 | -17.05 |
| 2025-05-09 | -16.70 |
| 2025-05-08 | -16.98 |
| 2025-05-07 | -16.94 |
| 2025-05-06 | -16.73 |
| 2025-05-05 | -17.37 |
| 2025-05-02 | -17.89 |
| 2025-05-01 | -18.58 |
| 2025-04-30 | -18.93 |
| 2025-04-29 | -19.32 |
| 2025-04-28 | -18.78 |